Results 51 to 60 of about 14,154 (120)

Resistance patterns of the 25 sequences with nucleoside reverse transcriptase inhibitor (NRTI) mutations analyzed on the Stanford HIV database.

open access: yes, 2019
Resistance patterns of the 25 sequences with nucleoside reverse transcriptase inhibitor (NRTI) mutations analyzed on the Stanford HIV database.
Damian Nota Anong (4911604)   +6 more
core   +1 more source

Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms [PDF]

open access: yes, 2004
The availability of durable, effective antiretroviral therapy for HIV-infected patients has fundamentally altered the prognosis of this disease and has also increased awareness that long-term drug toxicities have the potential to cause significant ...
Nolan, D., Mallal, S.
core  

Evidence of dual sexual transmission of multi-resistant HIV with two years persistence of resistance to NRTI and NNRTI: a case report

open access: yes, 2007
A case report of dual sexual transmission, with secondary transmission from naïve to naïve patient, of HIV harbouring K103N and L100I mutations, conferring full non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, plus 2 nucleoside ...
Mosti, S   +22 more
core   +1 more source

Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual

open access: yes
Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley   +1 more source

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

open access: yes, 2017
Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing ...
Miriam Lichtner   +29 more
core   +2 more sources

Dosing of NRTI antiretroviral drugs in the ARROW trial using WHO weightbands based on body surface area [17].

open access: yes, 2013
Dosing of NRTI antiretroviral drugs in the ARROW trial using WHO weightbands based on body surface area [17].
Jessica Tezikyabbiri (324179)   +8 more
core   +1 more source

Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–All tenofovir discontinuations.

open access: yes, 2016
Composition of the NRTI back-bone of the regimen started after the discontinuation of tenofovir (rows), according to the initial third drug (columns)–All tenofovir discontinuations.
Alessandro Cozzi-Lepri (195759)   +11 more
core   +1 more source

Differential effects of nucleoside reverse transcriptase inhibitor (NRTI) regimens on adipocyte mitochondrial DNA depletion in HIV-infected patients

open access: yes, 2004
BACKGROUND: Clinical trials data have provided strong evidence that NRTI therapy significantly influences risk of lipoatrophy. Here we examine associations between stavudine, zidovudine and non-thymidine NRTI regimens, as well as demographic and HIV ...
McKinnon, E.   +4 more
core  

Raltegravir plus a boosted protease inhibitor: experience in patients with resistance and/or NRTI-re-lated adverse events

open access: yes, 2010
Objectives : to evaluate the efficacy and safety of a dual therapy of raltegravir (RAL) and ritonavir-boosted protease inhibitor (PIr) in patients with resistance and/or NRTI-related adverse events.
L. Sighinolfi   +6 more
core   +1 more source

The prevalence of each NRTI-associated surveillance drug-resistance mutation in this meta-analysis versus in NRTI-experienced individuals in the same regions according to HIVDB.

open access: yes, 2015
The Spearman’s rank correlation coefficient (rho) and the p-value are shown in each plot. The number of isolates from NRTI-experienced individuals were 4,522, 2,218, 4,164, and 13,522 for SSA, SSEA, Latin America/Caribbean, and the pooled upper-income ...
Lynn Morris (7883)   +72 more
core   +1 more source

Home - About - Disclaimer - Privacy